Company: Kiniksa Pharmaceuticals, Ltd.
Symbol: KNSA
Description: They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
Trade Date: 5/24
Shares: 7 million
Price Range: $17.00-$19.00
Underwriter(s): Goldman Sachs, J.P. Morgan
Co-Manager(s): JMP Securities, Wedbush PacGrow
Terms Added: 5-14-18
Business: They have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. They have three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. They believe that each of their product candidates has the potential to address multiple indications.
Insider Buying: Certain of their directors and existing shareholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $50.0 million of their ordinary shares in this offering.
Agreement(s): This company has agreements with Regeneron Pharmaceuticals, Inc., or Regeneron, MedImmune, Limited, or MedImmune, Biogen MA Inc., or Biogen, Novo Nordisk A/S, or Novo Nordisk.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish